Politics
Senator Rand Paul has introduced a resolution to repeal the FDA's LDT Final Rule. He has been a vocal opponent to VALID and the introducer of VITAL. Despite your politics, Senator Paul has been a defender of the interests of small labs and clinical lab innovation. I got to meet him in DC a few years ago. Check out the details of his new resolution here: https://lnkd.in/e5BTsZQb.
🚨 NEW POLICY BLOG 🚨: "What You Need to Know About the Alliance for Hippocratic Medicine v. FDA Supreme Court Case" Get all the facts of the case and the summary of today's arguments here: https://bit.ly/3PFzhbH
VTA’s Executive Director, Tony Abboud, was quoted in the The Washington Post last week. He talked about the Supreme Court’s #TritonCase and the need for immediate policy change at the FDA. https://lnkd.in/eRTfgFvK
In our March newsletter, Tahir Amin discusses: 🔹 How the Affordable Prescriptions for Patients Act will help manage patent thickets but why Congress must go further to put an end to patent abuse once and for all. 🔹 The neo-colonial and neoliberal power dynamics at play in the World Health Organization Pandemic Accord negotiations. 🔹 A new op-ed from Alex Moss and Timi Iwayemi explaining just how dangerous Senator Coons (D-DE) and Senator Tillis’s (R-NC) PERA and PREVAIL acts are. https://lnkd.in/enUhzPkK
Experience the power of convergence: Uniting Medicaid & government pricing, drug pricing transparency, and commercial pricing & contracts into one exceptional event. https://lnkd.in/eiZQHq5Y
Did you know? Science 37 has been pioneering remote clinical trials for a decade (since 2014)! In this video, listen to Chief Medical Officer Dr. Jonathan Cotliar discuss the evolving regulatory landscape and how our Virtual Site model aligns with the latest FDA Draft Guidance. Watch the full "10 Things You Didn't Know About a Virtual Site" webinar recording here: https://lnkd.in/eU_vXT8J #clinicalresearch #clinicaltrials #virtualtrials
On March 21, 2024, the House Energy and Commerce held a subcommittee hearing titled “Evaluating Approaches to Diagnostic Test Regulation and the Impact of the FDA’s Proposed Rule.” In their recent blog post entitled: Congressional Hearing on LDTs: Split on FDA Regulation but Support for VALID, Jeff Gibbs and Ana Loloei write about the hearing, including witnesses, testimonies and what the next steps are. Read their blog post here: https://lnkd.in/e3ZMzg-R #fda #ivd #medicaldevices
Feeling unsure about the FDA’s clinical trial diversity requirements? You’re not alone! Our regulatory experts get many questions about these ever-evolving guidelines, so we wrote a white paper that answers all of them. Download it now: https://ow.ly/pQ7c50R791g #clinicaltrialdiversity #clinicaltrials #clinicalresearch
Top thing on my mind this morning: The conversations surrounding GLP-1s will continue throughout 2025. It may be, though, that the topic in those conversations will change. What will it be to start the year? It seems that the topic will be can we make these medications more available and less expensive. Maybe. This article lays out what is going on with the FDA, but buried at the bottom of this article are a couple of key things to keep watch for as well. One, a Maine resident is seeking class-action status for a suit over an employer-sponsored health plan's failure to pay for GLP-1 agonist prescriptions. Two, law firms are also trying to organize class-action suits over conditions such as blood clots and vision loss that have affected some people taking GLP-1 agonists. https://lnkd.in/gTK77Rer
Global Action was represented at the US Supreme Court during arguments in a case that could reshape FDA's regulation of e-cigarettes. Carter G. Phillips, our lawyer and the author of our amicus brief, explained the stakes to Bloomberg Law: https://lnkd.in/eg4zqfxA
Founder of da Vinci NCR Services LLC MS, BCBA, IBA, LBA | consultant specializing in employee health, wellness, & retention via Organizational Behavior Management (OBM) & NCR schedules Amplifying neurodivergent voices ♾️
When will the #FDA finalize their ruling on the proposed #ESD #ban; effectively prohibiting the practices of #CESS in Massachusetts & the #JudgeRotenburgCenter ? In contrast to their 2022 ruling; this year the FDA has ensured they have authority to maintain the ban and it will not be overturned; if approved. Keep an eye on the FDA press announcements at the link in this post & listen to #NDNABAthePodcast with Martin Slyngstad and Dan more details as the events unfurl. https://lnkd.in/g2fvTWih #StopTheShock #BanESDs You can also visit Bearded Behaviorist ‘s profile for more information on the subject matter. *CONTENT WARNING* electric shock discussed